Entrada Therapeutics, Inc. (TRDA) Stock Grade

About Entrada Therapeutics, Inc.'s fundamentals

Entrada Therapeutics is a small-cap biotechnology company with a market capitalization of $282.2 million that reported a substantial net loss in its latest annual statement, resulting in a negative net margin of -565.5%. The company experienced a dramatic 87.9% year-over-year revenue decline, indicating significant contraction in its business operations. As a pre-profitability biotech firm, Entrada does not pay dividends and lacks meaningful profitability metrics, which is typical for development-stage companies but reflects the financial challenges the company currently faces.